Khan Bilal Arshad 4

What Happened
Khan Bilal Arshad, a director of SpyGlass Pharma, reported two purchases on Feb 9, 2026: 20,000 shares and 115,000 shares, each at $16.00 per share, for a combined acquisition of 135,000 shares valued at approximately $2,160,000. Both transactions are coded "P" (purchase/open market or private purchase), which is a direct buy of stock rather than an option exercise or award.

Key Details

• Transaction dates/prices: Feb 9, 2026 — 20,000 shares @ $16.00; Feb 9, 2026 — 115,000 shares @ $16.00.
• Total acquired: 135,000 shares for ~$2,160,000.
• Shares owned after transaction: Not specified in the supplied Form 4 data.
• Footnote F1: Some shares are held by New World Medical, Inc.; Mr. Arshad is CEO of New World Medical and has voting/investment control over shares held by that entity but disclaims beneficial ownership except for any pecuniary interest.
• Filing: Form 4 filed Feb 11, 2026 reporting Feb 9 transactions — appears timely (filed within the SEC’s two-business-day window).

Context
These were outright purchases (code P), not option exercises, awards, or gifts. Purchases by insiders are often watched by investors as a potential positive signal, but they do not guarantee future company performance. The footnote clarifies that some holdings are through New World Medical, indicating institutional/affiliate holdings distinct from Mr. Arshad’s personal beneficial ownership.